This content is in French.
Bispecific antibodies in diffuse large B-cell lymphoma
14 février 2024
At least a third of patients with diffuse large B-cell lymphoma require a second or even third line of treatment for relapsed or refractory disease. New therapeutic approaches are being developed, such as chemoimmunotherapy and CAR-T-19 cell…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Asaad Trabolsi et al. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024 Feb 8;14(1):27.
View the source
